Filtered By:
Source: European Heart Journal
Condition: Atrial Fibrillation
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 120 results found since Jan 2013.
Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices)
Conclusions
Device-detected AF burden is associated with an increased risk of ischaemic stroke in a relatively unselected population of CIEDs patients. This finding may add to the basis for timely and clinically appropriate decision-making on anticoagulation treatment.
Source: European Heart Journal - February 21, 2014 Category: Cardiology Authors: Boriani, G., Glotzer, T. V., Santini, M., West, T. M., De Melis, M., Sepsi, M., Gasparini, M., Lewalter, T., Camm, J. A., Singer, D. E. Tags: Atrial fibrillation Source Type: research
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial
Conclusion
Apixaban had similar beneficial effects on stroke or systemic embolism and major bleeding compared with warfarin, irrespective of concomitant aspirin use.
Source: European Heart Journal - January 21, 2014 Category: Cardiology Authors: Alexander, J. H., Lopes, R. D., Thomas, L., Alings, M., Atar, D., Aylward, P., Goto, S., Hanna, M., Huber, K., Husted, S., Lewis, B. S., McMurray, J. J. V., Pais, P., Pouleur, H., Steg, P. G., Verheugt, F. W. A., Wojdyla, D. M., Granger, C. B., Wallentin, Tags: Atrial fibrillation Source Type: research
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF
Conclusion
Patients with PAD in ROCKET AF did not have a statistically significant higher risk of stroke or systemic embolism than patients without PAD, and there were similar efficacy outcomes in patients treated with rivaroxaban and warfarin. In PAD patients, there was a higher risk of major bleeding or NMCR bleeding with rivaroxaban when compared with warfarin (interaction P = 0.037). Further investigation is warranted to validate this subgroup analysis and determine the optimal treatment in this high-risk cohort of AF patients with PAD.
Source: European Heart Journal - January 21, 2014 Category: Cardiology Authors: Jones, W. S., Hellkamp, A. S., Halperin, J., Piccini, J. P., Breithardt, G., Singer, D. E., Fox, K. A. A., Hankey, G. J., Mahaffey, K. W., Califf, R. M., Patel, M. R. Tags: Atrial fibrillation Source Type: research
Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke
Conclusion
After the diagnosis of incident atrial fibrillation in older adults, mortality was the most frequent major outcome during the first 5 years. Among non-fatal cardiovascular events, heart failure was the most common event.
Source: European Heart Journal - January 21, 2014 Category: Cardiology Authors: Piccini, J. P., Hammill, B. G., Sinner, M. F., Hernandez, A. F., Walkey, A. J., Benjamin, E. J., Curtis, L. H., Heckbert, S. R. Tags: Atrial fibrillation Source Type: research
Prognostic significance of prolonged PR interval in the general population
Conclusion
In the middle-aged general population, prolonged PR interval normalizes in a substantial proportion of subjects during the time course, and it is not associated with an increased risk of all-cause or cardiovascular mortality.
Source: European Heart Journal - January 7, 2014 Category: Cardiology Authors: Aro, A. L., Anttonen, O., Kerola, T., Junttila, M. J., Tikkanen, J. T., Rissanen, H. A., Reunanen, A., Huikuri, H. V. Tags: Arrhythmia/electrophysiology Source Type: research
Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial
Conclusion
Renal impairment (CrCl <60 mL/min) doubles the risk of stroke and increased the risk of major bleeding by almost 60% in anticoagulated patients with AF. Renal impairment was additive to stroke risk prediction scores based on a significant NRI, but no significant improvement in discrimination ability (based on c-indexes) for CHA2DS2VASc or CHADS2 was observed.
Source: European Heart Journal - December 7, 2013 Category: Cardiology Authors: Apostolakis, S., Guo, Y., Lane, D. A., Buller, H., Lip, G. Y. H. Tags: Atrial fibrillation Source Type: research
A new look at atrial fibrillation: lessons learned from drugs, pacing, and ablation therapies
Atrial fibrillation (AF) is the most common arrhythmia and among the leading causes of stroke and heart failure in Western populations. Despite the increasing size of clinical trials assessing the efficacy and safety of AF therapies, achieved outcomes have not always matched expectations. Considering that AF is a symptom of many possible underlying diseases, clinical research for this arrhythmia should take into account their respective pathophysiology. Accordingly, the definition of the study populations to be included should rely on the established as well as on the new classifications of AF and take advantage from a dif...
Source: European Heart Journal - September 14, 2013 Category: Cardiology Authors: Kappenberger, L. Tags: REVIEWS Source Type: research
Secondary prevention by stroke subtype: a nationwide follow-up study in 46 108 patients after acute ischaemic stroke
Conclusions
Our study demonstrated that stroke subtype affects prognosis and also determines the effectiveness of secondary prevention.
Source: European Heart Journal - September 14, 2013 Category: Cardiology Authors: Kim, D., Lee, S.-H., Joon Kim, B., Jung, K.-H., Yu, K.-H., Lee, B.-C., Roh, J.-K., for Korean Stroke Registry investigators Tags: Atrial fibrillation Source Type: research
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial
Conclusion
The risks of stroke, mortality, and major bleeding were lower with apixaban than warfarin regardless of AF type and duration. Although the risk of stroke or systemic embolism was lower in paroxysmal than persistent or permanent AF, apixaban is an attractive alternative to warfarin in patients with AF and at least one other risk factor for stroke, regardless of the type or duration of AF.
Source: European Heart Journal - August 14, 2013 Category: Cardiology Authors: Al-Khatib, S. M., Thomas, L., Wallentin, L., Lopes, R. D., Gersh, B., Garcia, D., Ezekowitz, J., Alings, M., Yang, H., Alexander, J. H., Flaker, G., Hanna, M., Granger, C. B. Tags: Arrhythmia/electrophysiology Source Type: research
EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in specific clinical situations. This text is an executive summary of a practical guide that the European Heart Rhythm Association (EHRA) has assembled to help physicians in the use of the different NOACs. The full text is being published in EP Europace. Practical answers have been formulated for 15 concrete clinical scenarios: (i) practical start-up and follow-up scheme for ...
Source: European Heart Journal - July 14, 2013 Category: Cardiology Authors: Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., Kirchhof, P. Tags: SPECIAL ARTICLE Source Type: research
Biomarkers in atrial fibrillation: a clinical review
Assessment of atrial fibrillation (AF)-associated stroke risk is at present mainly based on clinical risk scores such as CHADS2 and CHA2DS2-VASc, although these scores provide only modest discrimination of risk for individual patients. Biomarkers derived from the blood may help refine risk assessment in AF for stroke outcomes and for mortality. Recent studies of biomarkers in AF have shown that they can substantially improve risk stratification. Cardiac biomarkers, such as troponin and natriuretic peptides, significantly improve risk stratification in addition to current clinical risk stratification models. Similar finding...
Source: European Heart Journal - May 21, 2013 Category: Cardiology Authors: Hijazi, Z., Oldgren, J., Siegbahn, A., Granger, C. B., Wallentin, L. Tags: REVIEW Source Type: research
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
Conclusion
Betrixaban was well tolerated and had similar or lower rates of bleeding compared with well-controlled warfarin in patients with AF at risk for stroke.
Source: European Heart Journal - May 21, 2013 Category: Cardiology Authors: Connolly, S. J., Eikelboom, J., Dorian, P., Hohnloser, S. H., Gretler, D. D., Sinha, U., Ezekowitz, M. D. Tags: Arrhythmia/electrophysiology Source Type: research
Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?
The objective of this review article is to provide an overview of stroke and bleeding risk assessment in AF. There would be particular emphasis on when, how, and why to use these risk stratification schemes, with a specific focus on the CHADS2 [congestive heart failure, hypertension, age, diabetes, stroke (doubled)], CHA2DS2-VASc [congestive heart failure or left ventricular dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74 and sex category (female)], and HAS-BLED [hypertension (i.e. uncontrolled blood pressure), abnormal renal/liver function, stroke, bleeding his...
Source: European Heart Journal - April 7, 2013 Category: Cardiology Authors: Lip, G. Y. H. Tags: REVIEWS Source Type: research
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy
Conclusion
The CHA2DS2-VASc score reclassifies 26% of patients with a CHADS2 score of 1 to a low annual risk of SSE of 1%. This risk seems low enough to consider withholding anticoagulant treatment.
Source: European Heart Journal - January 14, 2013 Category: Cardiology Authors: Coppens, M., Eikelboom, J. W., Hart, R. G., Yusuf, S., Lip, G. Y. H., Dorian, P., Shestakovska, O., Connolly, S. J. Tags: Arrhythmia/electrophysiology Source Type: research
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
Conclusion
Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit.
Source: European Heart Journal - January 14, 2013 Category: Cardiology Authors: Davidson, T., Husberg, M., Janzon, M., Oldgren, J., Levin, L.-A. Tags: Arrhythmia/electrophysiology Source Type: research